Business · 28/09/2015Updated: 10/17/2026 · 1 min read
FDA Announces Fee Rate for Rare Pediatric Disease Priority Review Voucher for Fiscal Year 2016
Summary
The US Food and Drug Administration (FDA) has set the fee rate for using a rare pediatric disease priority review voucher for fiscal year 2016, based on the average costs incurred by the agency in reviewing human drug applications in the previous year.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →